Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Metabolic function of the hepatic GLP-1-Wnt-FGF-21 axis

FY 2018-19

Summary
Fibroblast growth factor 21 (FGF-21) is an endocrine hormone mainly produced in the liver and released during fasting, functioning as an insulin signaling sensitizer. FGF-21 and its homologues are intensively studied in pre-clinical studies and in clinical trials. These homologues may become a novel category of pharmacological agents for patients with impaired glucose and lipid metabolism. Recently, we found that in LTCFDN, a Wnt signaling deficient mouse model generated in our lab, hepatic FGF-21 mRNA and protein levels were reduced, associated with impaired glucose and lipid homeostasis. As the incretin hormone glucagon-like peptide-1 (GLP-1) and its based drugs (i.e. exenatides and liraglutide) were shown to exert metabolic beneficial effects via up-regulating Wnt pathway effector ?-catenin, we propose the existence of the hepatic GLP-1-Wnt-FGF-21 axis in mediating the function of GLP-1 and its based drugs. Our lab is now aiming to examine the role of this signaling axis in health and diseases. My research project will focus mainly on exploring mechanisms underlying hepatic FGF-21 transcription. I hypothesize that FGF-21 is positively regulated by the Wnt signaling pathway effector ?-catenin/TCF, and that GLP-1 can exert its hepatic metabolic beneficial effects by activating FGF-21 production. This is achieved by stimulating both ?-catenin Ser675 phosphorylation and expression of the TCF family members. We are studying a novel signaling axis, which will deepen our knowledge on the two key metabolic hormones in the liver. We link the starvation hormone FGF-21 with the postprandial active hormone GLP-1 in this axis together, which may lead to novel therapeutic possibilities in treating impaired glucose and lipid metabolism.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
406286
Name
Badakhshi Yasaman
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Metabolic function of the hepatic GLP-1-Wnt-FGF-21 axis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
B-Catenin; Exenatide; Fibroblast Growth Factor 21; Glucagon-Like Peptide-1; Insulin; Liraglutide; Liver; Obesity; Type 2 Diabetes; Wnt
Abstract
Fibroblast growth factor 21 (FGF-21) is an endocrine hormone mainly produced in the liver and released during fasting, functioning as an insulin signaling sensitizer. FGF-21 and its homologues are intensively studied in pre-clinical studies and in clinical trials. These homologues may become a novel category of pharmacological agents for patients with impaired glucose and lipid metabolism. Recently, we found that in LTCFDN, a Wnt signaling deficient mouse model generated in our lab, hepatic FGF-21 mRNA and protein levels were reduced, associated with impaired glucose and lipid homeostasis. As the incretin hormone glucagon-like peptide-1 (GLP-1) and its based drugs (i.e. exenatides and liraglutide) were shown to exert metabolic beneficial effects via up-regulating Wnt pathway effector ?-catenin, we propose the existence of the hepatic GLP-1-Wnt-FGF-21 axis in mediating the function of GLP-1 and its based drugs. Our lab is now aiming to examine the role of this signaling axis in health and diseases. My research project will focus mainly on exploring mechanisms underlying hepatic FGF-21 transcription. I hypothesize that FGF-21 is positively regulated by the Wnt signaling pathway effector ?-catenin/TCF, and that GLP-1 can exert its hepatic metabolic beneficial effects by activating FGF-21 production. This is achieved by stimulating both ?-catenin Ser675 phosphorylation and expression of the TCF family members. We are studying a novel signaling axis, which will deepen our knowledge on the two key metabolic hormones in the liver. We link the starvation hormone FGF-21 with the postprandial active hormone GLP-1 in this axis together, which may lead to novel therapeutic possibilities in treating impaired glucose and lipid metabolism.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Badakhshi, Yasaman
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~